Your browser doesn't support javascript.
loading
Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses.
Raman, Sathya N Thulasi; Zetner, Adrian; Hashem, Anwar M; Patel, Devina; Wu, Jianguo; Gravel, Caroline; Gao, Jun; Zhang, Wanyue; Pfeifle, Annabelle; Tamming, Levi; Parikh, Karan; Cao, Jingxin; Tam, Roger; Safronetz, David; Chen, Wangxue; Johnston, Michael J W; Wang, Lisheng; Sauve, Simon; Rosu-Myles, Michael; Domselaar, Gary Van; Li, Xuguang.
Affiliation
  • Raman SNT; Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
  • Zetner A; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
  • Hashem AM; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Patel D; Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Wu J; Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
  • Gravel C; Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
  • Gao J; Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
  • Zhang W; Centre for Vaccines Clinical Trials and Biostatistics, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, Canada.
  • Pfeifle A; Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
  • Tamming L; Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
  • Parikh K; Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
  • Cao J; Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
  • Tam R; Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
  • Safronetz D; Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
  • Chen W; Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
  • Johnston MJW; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
  • Wang L; Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
  • Sauve S; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
  • Rosu-Myles M; Human Health Therapeutics Research Center, National Research Council of Canada, Ottawa, Canada.
  • Domselaar GV; Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
  • Li X; Department of Chemistry, Carleton University, Ottawa, Canada.
Emerg Microbes Infect ; 12(1): 2192821, 2023 Dec.
Article in En | MEDLINE | ID: mdl-36927227
ABSTRACT
Influenza and Respiratory Syncytial virus (RSV) infections together contribute significantly to the burden of acute lower respiratory tract infections. Despite the disease burden, no approved RSV vaccine is available. While approved vaccines are available for influenza, seasonal vaccination is required to maintain protection. In addition to both being respiratory viruses, they follow a common seasonality, which warrants the necessity for a concerted vaccination approach. Here, we designed bivalent vaccines by utilizing highly conserved sequences, targeting both influenza A and RSV, as either a chimeric antigen or individual antigens separated by a ribosome skipping sequence. These vaccines were found to be effective in protecting the animals from challenge by either virus, with mechanisms of protection being substantially interrogated in this communication.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Influenza Vaccines / Respiratory Syncytial Virus Infections / Influenza, Human Limits: Animals / Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Influenza Vaccines / Respiratory Syncytial Virus Infections / Influenza, Human Limits: Animals / Humans Language: En Year: 2023 Type: Article